News Release

New gene may provide breast cancer diagnostic marker

Peer-Reviewed Publication

PLOS

In a research article published in this week's PLoS Medicine, Ann Killary (from the University of Texas M. D. Anderson Cancer Center) and colleagues describe a new gene called DEAR1 that is genetically altered by mutation and deletion in breast tumors, and that may provide a new breast cancer prognostic marker.

Each year, more than one million women discover that they have breast cancer. Although breast cancer is usually diagnosed in women in their 50s or 60s, some women develop breast cancer much earlier. Cancer in younger women tends to be more likely to recur or spread, and young women with breast cancer have a lower overall survival rate than older women with cancer. It would therefore be particularly useful to be able to identify those young women who are specifically at the greatest risk of cancer recurrence, so that they could be offered intensive surveillance.

In this study, the researchers used a genetic technique termed "suppression subtractive hybridization" to identify a new gene that is located on Chromosome 1 in a region where loss of heterozygosity (a specific type of genetic alteration) regularly occurs. They called the gene ductal epithelium-associated RING Chromosome 1, or DEAR1. Further analysis of a series of 14 samples showed that DEAR1 protein expression was reduced or lost in 71% of ductal carcinomas in situ (abnormalities that can develop into breast cancer). Sequence analysis of 55 primary breast tumors obtained from The University of Texas M. D. Anderson Cancer tumor bank also showed that 13% contained genetic alterations in DEAR1.

In addition, Ann Killary and colleagues found that DEAR1 expression was frequently lost in women with early-onset breast cancer and the loss of DEAR1 expression correlated with a strong family history of breast cancer and with a breast cancer subtype that has a poor outcome. At 5-year follow-up of a cohort of 123 pre-menopausal women with onset of breast cancer between the ages of 25 and 49 years, DEAR1-positive expression correlated significantly with a 95% local recurrence-free survival.

Although laboratory experiments may not necessarily reflect what happens in people, the authors say that these findings "indicate that DEAR1 expression is an independent predictor of local recurrence in early-onset breast cancers and suggest that DEAR1-negative staining on immunohistochemistry could be an important marker to stratify early-onset breast cancer patients for increased vigilance in follow-up and adjuvant therapy."

In a related expert commentary on the new study, Senthil K. Muthuswamy from the Ontario Cancer Institute, Toronto, Canada, who was not involved with the original study, says "these observations identify DEAR1 as an excellent predictive biomarker for early onset breast cancers".

###

Funding: This research was supported by grants from the Texas Advanced Research Program, the US Department of Defense, and the US National Cancer Institute Early Detection Research Network to AMK. STL and DSC were supported by the US National Cancer Institution training grant (T32 CA09299), STL by the US National Kidney Foundation, and DSC by the Ladies Auxiliary to the Veterans of Foreign Wars. The M. D. Anderson core facilities for DNA sequencing, peptide synthesis, nucleic acid extraction, and histopathology are supported by a grant from the US National Cancer Institute (NCI CA-16672). Funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: Three of the authors (Steven T. Lott, Dawn S. Chandler and Ann McNeill Killary) are co-inventors named in the US Patent #6,943,245 granted 9/13/2005 and US Patent #7,169,384 granted 1/30/2007 to the University of Texas M. D. Anderson Cancer Center regarding the novel gene DEAR1 described herein.

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.1000068

Citation: Lott ST, Chen N, Chandler DS, Yang Q, Wang L, et al. (2009) DEAR1 Is a Dominant Regulator of Acinar Morphogenesis and an Independent Predictor of Local Recurrence-Free Survival in Early-Onset Breast Cancer. PLoS Med 6(5): e1000068. doi:10.1371/journal.pmed.1000068

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-06-05-killary.pdf

READ THE EDITORS' SUMMARY OF THE PAPER: http://www.plos.org/press/plme-06-05-killary-summary.pdf

CONTACT:
University of Texas M. D. Anderson Cancer Center
Genetics
1515 Holcombe Blvd
Houston, Texas 77030
United States of America
+1 713-834-6395
+1 713-792-1474 (fax)
akillary@mdanderson.org

Related PLoS Medicine Perspective:

Citation: Muthuswamy SK (2009) A New Tumor Suppressor That Regulates Tissue Architecture. PLoS Med 6(5): e1000073. doi:10.1371/journal.pmed.1000073

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.1000073

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-06-05-muthuswamy.pdf

CONTACT:
Senthil K. Muthuswamy
Cold Spring Harbor Laboratory
Muthuswamy Lab
One Bungtown road
Cold Spring Harbor, 11724
United States of America
+1 516 367 6975
muthuswa@cshl.edu


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.